Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Upfront continuous BTK inhibitor (BTKi) versus time-limited venetoclax-BTKi combinations in CLL across IGHV subgroups: Results of an indirect analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

SMStefano MolicaUniversity of HullDADavid AllsupUniversity of Hull

Discussion

Loading...

Member takes

Overview

Indirect analysis reveals no significant difference in progression-free survival among CLL treatment methods, implying flexible selection based on patient factors.

Key Points

  • This research aims to compare treatment efficacy of BTK inhibitors and venetoclax-based therapies in CLL across IGHV subgroups.
  • Conducted an indirect comparative analysis of treatment outcomes from phase III trials
  • Evaluated continuous BTK inhibitor therapies and time-limited venetoclax-BTKi regimens
  • Used individual patient data to assess progression-free survival (PFS) over four years
  • No significant difference in four-year PFS among treatment groups
  • Progression-free survival was similar regardless of IGHV mutation status
  • Findings suggest treatment personalization based on patient factors can maintain efficacy.

Cite This Study

Molica et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d870https://doi.org/10.1182/blood-2025-3887
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement2025
  2. 2Real-world outcomes of bruton tyrosine kinase inhibitors versus venetoclax in chronic lymphocytic leukemia.2026
  3. 3Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis2025
  4. 4Real-world overall survival outcomes of BTK inhibitors vs. venetoclax-based therapy as second-line treatment for chronic lymphocytic leukemia.2026
  5. 5Long-term outcomes in high-risk patients with chronic lymphocytic leukemia treated with targeted therapies in the real-world2025